New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
Icotrokinra from Johnson & Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) is the first oral psoriasis therapy since Sotyktu deucravactinib to succeed in Phase III. Although it’s not clear how differentiated on efficacy the IL-23R peptide antagonist will be from other oral therapies in development, the profile does appear favorable against Sotyktu.
The partners reported that icotrokinra, formerly JNJ77242113, met the primary endpoint in a pair of Phase III plaque psoriasis studies. In the 684-patient ICONIC-Lead trial, the placebo-adjusted percentage of patients who achieved an IGA3 score of 0/1 was 56.4, while the placebo-adjusted PASI 90 score was 45.2%. Results have yet to be reported from the secondary endpoints of PASI 75 and PASI 100...